Intero Biosystems develops stem-cell-derived human intestinal organoids that contain functioning neurons, blood vessels, muscle, and inner lining. These miniature organs are engineered to provide accurate human biology models for preclinical testing. The platform aims to accelerate drug discovery and improve patient outcomes by offering reliable and scalable in vitro systems.
Funding
Funding not disclosed
Founders
Product
Problem
Preclinical drug testing often relies on animal models or simplified cell cultures that fail to accurately replicate human intestinal physiology, leading to inaccurate predictions of drug efficacy and safety in humans. This can result in costly clinical trial failures and delays in bringing effective treatments to market.
Solution
Intero Biosystems' GastroScreen is a stem-cell-derived human intestinal organoid designed to mimic the structure and function of the human intestine for preclinical drug testing. GastroScreen contains key intestinal components, including neurons, blood vessels, muscle, and the inner lining of the intestine, providing a more physiologically relevant model than traditional methods. By testing drugs on GastroScreen, pharmaceutical companies can evaluate drug efficacy and safety in a human-like environment, potentially reducing the risk of clinical trial failures and accelerating drug development.
Target Audience
The primary customers are pharmaceutical companies and research institutions involved in preclinical drug development and seeking more accurate and predictive models for evaluating drug efficacy and safety.
Features
- Stem-cell-derived human intestinal organoid that replicates human intestinal function
- Contains functioning neurons, blood vessels, muscle, and the inner lining of the intestine
- Provides a more accurate and predictive model for preclinical drug testing compared to animal models or cell cultures
- Enables evaluation of drug efficacy and safety in a human-like environment